Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

Core Insights - Longeveron Inc. has received a patent from the USPTO for its proprietary Mesenchymal Stem Cells (MSCs) aimed at treating aging-related frailty, valid until 2038 [1][2] - The patent covers methods of administering MSCs to patients suffering from aging-related frailty, a condition characterized by weakness, low physical activity, and other debilitating symptoms [3][8] - The company has conducted Phase 1 and 2 clinical trials demonstrating positive results in improving physical functioning in patients with aging-related frailty [4][8] Company Overview - Longeveron is a clinical stage biotechnology company focused on developing regenerative medicines to address unmet medical needs, with its lead product being laromestrocel (Lomecel-B), derived from young healthy adult donors [6] - Laromestrocel is designed to have multiple mechanisms of action, including anti-inflammatory and pro-vascular effects, with potential applications across various diseases [5][6] - The company is pursuing three main pipeline indications: hypoplastic left heart syndrome, Alzheimer's disease, and pediatric dilated cardiomyopathy, and has received several FDA designations for its programs [6]